Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 08, 2021 08:00 ET | Source: Scopus BioPharma Inc.

Scopus BioPharma Announces Adjournment of Annual Meeting of Stockholders

NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”) today announced that, on November 5, 2021, its 2021 Annual Meeting of Stockholders (the “Annual Meeting”) was...
October 08, 2021 17:30 ET | Source: Scopus BioPharma Inc.

Scopus BioPharma Announces Adjournment of Annual Meeting of Stockholders

NEW YORK, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with...
October 05, 2021 08:45 ET | Source: Scopus BioPharma Inc.

Scopus BioPharma to Present at the LD Micro Main Event

Scopus to present on the recent launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology Presentation to include a discussion of preclinical data released at the 17th...
October 01, 2021 16:30 ET | Source: Scopus BioPharma Inc.

Scopus BioPharma Retaining Counsel to Investigate Unusual Market Activity

NEW YORK, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company, announced today that it is retaining Boies Schiller Flexner LLP to...
October 01, 2021 07:00 ET | Source: Scopus BioPharma Inc.

Scopus BioPharma to Present at MicroCap Rodeo’s Fall Harvest Best Ideas Conference

Scopus to present on the recent launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology Presentation to include a discussion of preclinical data released at the 17th...
September 29, 2021 08:30 ET | Source: Scopus BioPharma Inc.

Scopus BioPharma's Subsidiary — Duet Therapeutics — Announces Release of Preclinical Data Being Presented at 17th Annual Meeting of the Oligonucleotide Therapeutics Society

Data from two different studies benchmark Duet’s proprietary bifunctional oligonucleotides against immune checkpoint inhibitors (“Checkpoint Inhibitors”) in lymphoma and prostate tumor models in mice ...
September 28, 2021 09:15 ET | Source: Scopus BioPharma Inc.

Scopus BioPharma’s Subsidiary Duet Therapeutics Set to Release Scientific Data During the 17th Annual Meeting of the Oligonucleotide Therapeutics Society

NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with...
September 28, 2021 06:30 ET | Source: Scopus BioPharma Inc.

Scopus BioPharma’s Subsidiary — Duet Therapeutics — Set to Release Scientific Data During the 17th Annual Meeting of the Oligonucleotide Therapeutics Society

NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with...
September 28, 2021 06:00 ET | Source: Scopus BioPharma Inc.

Scopus BioPharma to Adjourn 2021 Annual Meeting of Stockholders

NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with...
September 23, 2021 08:30 ET | Source: Scopus BioPharma Inc.

Scopus BioPharma to Present at the Benzinga Healthcare Small Cap Conference

NEW YORK, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with...